Suppliers and packagers for ZORTRESS

ZORTRESS

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novartis	ZORTRESS	everolimus	TABLET;ORAL	021560	NDA	Novartis Pharmaceuticals Corporation	0078-0414-20	60 BLISTER PACK in 1 BOX (0078-0414-20) / 1 TABLET in 1 BLISTER PACK (0078-0414-61)	2010-04-22
Novartis	ZORTRESS	everolimus	TABLET;ORAL	021560	NDA	Novartis Pharmaceuticals Corporation	0078-0415-20	60 BLISTER PACK in 1 BOX (0078-0415-20) / 1 TABLET in 1 BLISTER PACK (0078-0415-61)	2010-04-22
Novartis	ZORTRESS	everolimus	TABLET;ORAL	021560	NDA	Novartis Pharmaceuticals Corporation	0078-0417-20	60 BLISTER PACK in 1 BOX (0078-0417-20) / 1 TABLET in 1 BLISTER PACK (0078-0417-61)	2010-04-22
Novartis	ZORTRESS	everolimus	TABLET;ORAL	021560	NDA	Novartis Pharmaceuticals Corporation	0078-0422-20	60 BLISTER PACK in 1 BOX (0078-0422-20) / 1 TABLET in 1 BLISTER PACK (0078-0422-61)	2010-04-22

Suppliers and packagers for ZORTRESS

Last updated: May 28, 2026

ZORTRESS (voriconazole?) suppliers: who manufactures and supplies the drug active ingredient and finished product

ZORTRESS is the brand name for everolimus (mTOR inhibitor). Pfizer historically marketed ZORTRESS in the US, but the supply chain depends on the specific dosage form and strength and the region. Based on publicly listed FDA and label supply-chain information, the finished dose is produced through a multi-party manufacturing network that typically includes a contract manufacturer for drug product and separate suppliers for active pharmaceutical ingredient (API) and key intermediates.

What companies supply ZORTRESS (everolimus) drug product manufacturing?

Finished-dose supply typically sits with one or more contract manufacturers under label/CMC arrangements, with the sponsor holding regulatory responsibility for FDA filings.

Where does ZORTRESS drug product come from (contract manufacturing)?

ZORTRESS tablets/capsules are generally produced by a contract manufacturing site named in regulatory submissions and label manufacturing sections. The “Supplier” list that matters for procurement is the commercial drug product manufacturer and any secondary packagers.

How to identify the actual drug product supplier

Use the “Manufactured for” / “Distributed by” / “Manufactured at” sections of the US prescribing information and the FDA drug label record to map:

• NDA holder / labeler (regulatory responsible party)
• Drug product manufacturer site(s)
• Packaging/labeling and secondary packaging sites

Who supplies the everolimus API for ZORTRESS?

ZORTRESS uses everolimus. API supply typically includes:

• An API manufacturer (everolimus active)
• Intermediate suppliers (synthetic intermediates)
• Solvent and reagent suppliers are not typically named publicly, so procurement focus is API and critical intermediates.

How API supply is structured

Everolimus API is produced in a regulated chemical manufacturing process and then supplied to the drug product manufacturer for final formulation and finishing.

Which ZORTRESS suppliers matter most for generic or biosimilar risk?

For exclusivity and entry risk, the practical supply-chain question is whether a generic applicant can source:

• The same solid state attributes and excipients profile
• Bioequivalent drug product manufactured under comparable process controls
• Everolimus API that meets the same specifications

What procurement constraints block fast substitution

• API qualification and change controls for drug product manufacturers
• Process lock-in effects tied to formulation and particle/solid-state properties
• Tight impurity and residual solvent specifications

What is the Orange Book status of ZORTRESS and how does it affect sourcing?

ZORTRESS is protected by a set of patents covering drug substance, composition, and potentially methods of use and/or manufacturing. Patent barriers shape which suppliers can participate through licensing or generic pathways.

How patent status changes “supplier availability”

• During active patent coverage, sourcing generally stays within the NDA holder’s supply chain plus authorized manufacturers.
• After expiration or successful Paragraph IV challenges (if applicable), generic firms can enter and bring new API-to-drug-product supply networks.

When does ZORTRESS lose exclusivity and when can new suppliers enter?

Exclusivity and patent expiration timing is the gating factor for new labelers and generic supply entrants.

Timeline drivers

• Primary patent expirations (drug substance or composition)
• Patent term adjustments
• Regulatory exclusivities (where applicable)
• Any litigation settlements that delay generic launches

What ZORTRESS patent estate features drive supplier licensing demands?

Patent scope determines whether a generic or licensed supplier must:

• Design around formulation/composition claims
• Negotiate a license or accept design-around costs

Common claim clusters that bind supply

• Composition-of-matter for the drug substance (everolimus)
• Formulation claims (tablet excipients, solid state, release profile)
• Method-of-use claims tied to transplant indications

What generic entry risks exist for ZORTRESS drug product supply?

Generic or biosimilar-like risks for small molecule everolimus products generally manifest as ANDAs for identical or bioequivalent formulations, unless product-form-specific differences exist.

Key risks procurement teams monitor

• FDA bioequivalence requirements and post-approval chemistry changes
• API requalification after any API source change
• Regulatory inspection outcomes at manufacturing sites

Which companies are challenging ZORTRESS and how does that change the supplier landscape?

When ANDA filings appear, they can indicate:

• Alternative API supply chains
• New drug product manufacturers moving into the market
• Potential settlements that preserve NDA holder supply

How to interpret “challenge” signals for sourcing

An ANDA filer’s manufacturing partner network often becomes visible in later FDA and litigation records, which procurement teams then treat as “candidate suppliers.”

How do ZORTRESS formulations affect which suppliers can make it?

Formulation drives supply qualification. Differences in:

• dosage form (tablet vs. dispersible or other)
• strength
• excipient set
• release characteristics determine which manufacturers can reproduce performance.

What to check when mapping suppliers by formulation

• Strength-specific drug product manufacturing sites
• Any site changes tied to CMC updates
• Specifications for dissolution, impurities, and particle/solid-state attributes

What do ZORTRESS supply contracts typically require from manufacturers?

Procurement and quality agreements for oncology/transplant agents usually require:

• GMP compliance at drug product sites
• Robust change control for API source switches
• Batch release testing and stability programs

Quality system bottlenecks

• Control of critical process parameters
• Validation of cleaning and cross-contamination controls
• Regulatory audit readiness for FDA and global regulators

Which countries supply ZORTRESS manufacturing and API?

ZORTRESS supply networks are typically global. The procurement question is not just “where are they made,” but “where can they be sourced with validated GMP status for your market.”

Region-specific supply

• US market suppliers are those listed in FDA labeling for drug product.
• EU and other markets depend on EMA filings and national authorization holders.
• Procurement plans often require parallel qualification for local distribution.

Key Takeaways

• ZORTRESS is everolimus-based; drug product and API come from distinct qualified manufacturing entities under regulatory oversight.
• The most actionable “supplier” list comes from the US label manufacturing sections and FDA records that identify the drug product manufacturer sites.
• Patent and exclusivity status determines whether new licensed/generic suppliers can enter, which in turn reshapes the sourcing landscape.
• Formulation and strength-specific CMC controls are decisive for qualifying alternative manufacturers, especially for generic substitution.

FAQs

1. How can I identify the exact drug product manufacturer for ZORTRESS for a specific strength?
   Check the “Manufactured at” sections in the FDA-approved prescribing information for each strength and compare against the latest label revision.

2. Do ZORTRESS API suppliers change over the product lifecycle?
   Yes, API source changes can occur through CMC updates and supplier substitutions, but each change requires qualification and regulatory notification/approval depending on the impact.

3. What parts of the ZORTRESS supply chain typically affect drug product quality most?
   API impurity profile control, solid-state/formulation attributes, and drug product dissolution performance are the primary quality drivers.

4. When generic ZORTRESS launches, what supplier changes usually show up first?
   New drug product manufacturing sites and a different API supply chain typically appear first in ANDA manufacturing and release testing infrastructure.

5. How do settlements and litigation impact supplier availability for ZORTRESS?
   They can delay generic approval or launch dates, preserving the NDA holder’s commercial supply chain until entry is permitted.

References

1. U.S. Food and Drug Administration. ZORTRESS (everolimus) prescribing information and drug label records.
2. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations for everolimus (ZORTRESS).